

WET AMD:

We understand what is
at the centre of your world



There is a global medical need for a more affordable treatment for wet age-related macular degeneration (AMD). The ALVOEYE Study is a clinical study researching an investigational medication that is a proposed 'biosimilar' to Eylea®, a wet AMD treatment that is already approved for use. This study may help improve patient access to wet AMD treatments.

We are looking for patients who:

- are 50 years of age or older
- have been diagnosed with wet AMD
- have not previously received any treatment for wet AMD.

Study participation will last for up to 56 weeks. Participants will be required to visit the study centre up to 13 times.

Pretoria Eye Institute
Clinical research department

T: 012 427 0000/2204/2315
E: research@eyeinstitute.co.za



Diversity among our clinical trial participants is important to us. We therefore request your help in considering referral of patients who reflect the population of people with wet AMD.

If you are aware of any patients who may be eligible for the ALVOEYE Study or would like further information, please contact us.

